Literature DB >> 15539009

Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.

Mark E Williams1.   

Abstract

Current treatment of the nephropathy complication of diabetes mellitus is suboptimal in halting the progression of the complex disease. Among the irreversible effects of sustained hyperglycemia is the heightened formation of advanced glycation end products (AGEs). The role of AGEs in diabetic nephropathy has been established by years of basic research. This article reports progression through human studies of the few AGE inhibitors that have reached clinical development, including pimagedine, pyridoxamine, and alagebrium.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15539009     DOI： 10.1007/s11892-004-0054-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  43 in total

1.  Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells.

Authors:  Margo P Cohen; Elizabeth Shea; Sheldon Chen; Clyde W Shearman
Journal:  J Lab Clin Med       Date:  2003-04

2.  Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals.

Authors:  R Sharma; A Khanna; M Sharma; V J Savin
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

Review 3.  Advanced glycation end products: a Nephrologist's perspective.

Authors:  D S Raj; D Choudhury; T C Welbourne; M Levi
Journal:  Am J Kidney Dis       Date:  2000-03       Impact factor: 8.860

Review 4.  Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.

Authors:  Sara Vasan; Peter Foiles; Hank Founds
Journal:  Arch Biochem Biophys       Date:  2003-11-01       Impact factor: 4.013

Review 5.  Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.

Authors:  Thomas O Metz; Nathan L Alderson; Suzanne R Thorpe; John W Baynes
Journal:  Arch Biochem Biophys       Date:  2003-11-01       Impact factor: 4.013

Review 6.  The importance of diabetic nephropathy in current nephrological practice.

Authors:  Francesco Locatelli; Bernard Canaud; Kai-Uwe Eckardt; Peter Stenvinkel; Christoph Wanner; Carmine Zoccali
Journal:  Nephrol Dial Transplant       Date:  2003-09       Impact factor: 5.992

7.  Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy.

Authors:  Alessandro Amore; Paola Cirina; Giovanni Conti; Franco Cerutti; Nayer Bagheri; Steven Noel Emancipator; Rosanna Coppo
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

8.  Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice.

Authors:  Margo P Cohen; Elizabeth Hud; Elizabeth Shea; Clyde W Shearman
Journal:  Metabolism       Date:  2002-07       Impact factor: 8.694

9.  The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.

Authors:  Nathan L Alderson; Mark E Chachich; Nancy N Youssef; Robert J Beattie; Maurice Nachtigal; Suzanne R Thorpe; John W Baynes
Journal:  Kidney Int       Date:  2003-06       Impact factor: 10.612

10.  Production of pseudodiabetic renal glomerular changes in mice after repeated injections of glucosylated proteins.

Authors:  B A McVerry; C Fisher; A Hopp; E R Huehns
Journal:  Lancet       Date:  1980-04-05       Impact factor: 79.321
View more
  6 in total

Review 1.  Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Authors:  Emaad M Abdel-Rahman; Lawand Saadulla; W Brian Reeves; Alaa S Awad
Journal:  J Gen Intern Med       Date:  2011-10-18       Impact factor: 5.128

Review 2.  Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complication.

Authors:  H Younus; S Anwar
Journal:  Int J Health Sci (Qassim)       Date:  2016-04

Review 3.  New potential agents in treating diabetic kidney disease: the fourth act.

Authors:  Mark E Williams
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Simulated microgravity-induced aortic remodeling.

Authors:  Eric C Tuday; Daniel Nyhan; Artin A Shoukas; Dan E Berkowitz
Journal:  J Appl Physiol (1985)       Date:  2009-03-19

Review 5.  The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach.

Authors:  Parveen Salahuddin; Gulam Rabbani; Rizwan Hasan Khan
Journal:  Cell Mol Biol Lett       Date:  2014-08-20       Impact factor: 5.787

6.  Ethyl Vanillin Protects against Kidney Injury in Diabetic Nephropathy by Inhibiting Oxidative Stress and Apoptosis.

Authors:  Yuna Tong; Shan Liu; Rong Gong; Lei Zhong; Xingmei Duan; Yuxuan Zhu
Journal:  Oxid Med Cell Longev       Date:  2019-11-12       Impact factor: 6.543
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.